Advocacy intelligence hub — real-time data for patient organizations
New Approaches to Neuroblastoma Therapy Consortium — PHASE2
Institut Curie — PHASE2
Tianjin Medical University Cancer Institute and Hospital — PHASE2
University of Florida — PHASE1, PHASE2
Children's National Research Institute — PHASE1
Tianjin Medical University Cancer Institute and Hospital — PHASE2
St. Jude Children's Research Hospital — PHASE2
Princess Maxima Center for Pediatric Oncology — PHASE1, PHASE2
University of Arizona — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Unituxin
United Therapeutics
DANYELZA
(naxitamab-gqgk)Orphan drugY-mAbs Therapeutics, Inc.
Unituxin
(dinutuximab)Orphan drugstandardUnited Therapeutics Corporation
Glycolipid Disialoganglioside-directed Antibody [EPC]
12.1 Mechanism of Action Dinutuximab binds to the glycolipid GD2. This glycolipid is expressed on neuroblastoma cells and on normal cells of neuroecto...
Iwilfin
(eflornithine)Orphan drugstandardUSWM, LLC
12.1 Mechanism of Action Eflornithine is an irreversible inhibitor of the enzyme ornithine decarboxylase (ODC), the first and rate-limiting enzyme in ...
Selim Corbacioglu, MD
University of Ulm, Germany
Yizhuo Zhang
Sun Yat-Sen University Cancer Center
Mitchell Cairo, MD, MD
New York Medical College
📍 HAWTHORNE, NY
Gudrun Schleiermacher, MD
Institut Curie
Kyoo H. Lee, MD
Asan Medical Center
Brian Kushner, MD, MD
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY